These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 9522840)

  • 41. Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine.
    Robert P
    Curr Med Res Opin; 2002; 18(3):156-71. PubMed ID: 12094826
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Alzheimer's disease: a progress report. How far the search for treatments has come and where it is heading.
    Harv Ment Health Lett; 2003 Nov; 20(5):1-4. PubMed ID: 14633486
    [No Abstract]   [Full Text] [Related]  

  • 43. Advances in the treatment of Alzheimer's disease.
    Schneider LS
    Aging (Milano); 1998 Apr; 10(2):156-7. PubMed ID: 9666210
    [No Abstract]   [Full Text] [Related]  

  • 44. PET studies and cholinergic therapy in Alzheimer's disease.
    Nordberg A
    Rev Neurol (Paris); 1999; 155 Suppl 4():S53-63. PubMed ID: 10637939
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Current treatments for Alzheimer's disease: cholinesterase inhibitors.
    Doody RS
    J Clin Psychiatry; 2003; 64 Suppl 9():11-7. PubMed ID: 12934969
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Alzheimer's disease: current status of etiopathogenesis and therapeutic strategies.
    Khairallah MI; Kassem LA
    Pak J Biol Sci; 2011 Feb; 14(4):257-72. PubMed ID: 21870628
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Alzheimer disease: Non-pharmacological and pharmacological management of cognition and neuropsychiatric symptoms.
    Loi SM; Eratne D; Kelso W; Velakoulis D; Looi JC
    Australas Psychiatry; 2018 Aug; 26(4):358-365. PubMed ID: 29671334
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New drugs for Alzheimer's disease.
    Delagarza VW
    Am Fam Physician; 1998 Oct; 58(5):1175-82. PubMed ID: 9787282
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Monoamine oxidase inhibitors, cognitive functions and neurodegenerative diseases.
    Delumeau JC; Bentué-Ferrer D; Gandon JM; Amrein R; Belliard S; Allain H
    J Neural Transm Suppl; 1994; 41():259-66. PubMed ID: 7931235
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
    Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J
    Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Medicinal and chemical approaches to focused search of agents for treatment and therapy of Alzheimer disease].
    Bachurin SO
    Vopr Med Khim; 2001; 47(2):155-97. PubMed ID: 11450439
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Presentation and stability of cognitive and noncognitive symptom patterns in patients with Alzheimer's disease. Disease course over a two-year period under constant treatment conditions with rivastigmine].
    Wobrock T; Retz-Junginger P; Retz W; Supprian T; Rösler M
    Fortschr Neurol Psychiatr; 2003 Apr; 71(4):199-204. PubMed ID: 12677553
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Selegiline in the treatment of Alzheimer's disease: a long-term randomized placebo-controlled trial. Czech and Slovak Senile Dementia of Alzheimer Type Study Group.
    Filip V; Kolibás E
    J Psychiatry Neurosci; 1999 May; 24(3):234-43. PubMed ID: 10354658
    [TBL] [Abstract][Full Text] [Related]  

  • 54. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer's disease and other dementias.
    Ihl R; Frölich L; Winblad B; Schneider L; Burns A; Möller HJ;
    World J Biol Psychiatry; 2011 Feb; 12(1):2-32. PubMed ID: 21288069
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacologic approaches to cognitive deficits in Alzheimer's disease.
    Peskind ER
    J Clin Psychiatry; 1998; 59 Suppl 9():22-7. PubMed ID: 9720483
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Accuracy of early diagnosis and its impact on the management and course of Alzheimer's disease.
    Chang CY; Silverman DH
    Expert Rev Mol Diagn; 2004 Jan; 4(1):63-9. PubMed ID: 14711350
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cholinesterase inhibitors for the treatment of Alzheimer's disease in the elderly.
    VanDenBerg CM; Kazmi Y; Jann MW
    Drugs Aging; 2000 Feb; 16(2):123-38. PubMed ID: 10755328
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rivastigmine for Alzheimer's disease.
    Drug Ther Bull; 2000 Feb; 38(2):15-6. PubMed ID: 10829350
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [The treatment of Alzheimer's disease].
    Ankri J
    Rev Neurol (Paris); 2003 Sep; 159(8-9):819-24. PubMed ID: 13679729
    [No Abstract]   [Full Text] [Related]  

  • 60. Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease.
    Rombouts SA; Barkhof F; Van Meel CS; Scheltens P
    J Neurol Neurosurg Psychiatry; 2002 Dec; 73(6):665-71. PubMed ID: 12438467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.